Virtual Agent Feasibility in Oncology Patients (NTT Data)
The purpose of this study is to compare the use of a virtual agent vs. a human agent when onboarding oncology patients over the telephone to Remote Patient Monitoring (RPM) devices. RPM devices are instruments that a patient can use to measure their own weight and vital signs. Both the virtual and human agents will be available by telephone to instruct the patient on how to use the RPM devices to measure weight, blood pressure, heart rate, temperature, and oxygen saturation. Patients will be randomized to either the virtual or human agent, have assessments of their medical and oncological history, overall well-being, body measurements, and vital signs, and will complete questionnaires about their experience.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated May 29, 2026 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Health Services Research
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Duke University
- Interventions being studied
- Device: Virtual agent; Other: Human agent
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- 1. Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information. 2. Age ≥18 3. Cancer (solid tumor) 4. Planning to return to Duke Cancer Center clinic for three days in a row
- Patients whose treatment does not require that they return to clinic for three days in a row, but who are willing to voluntarily return to participate in this study are permitted to enroll. 5. Eastern Cooperative Oncology Group (ECOG) score of 0-2 6. Native fluency of spoken English as determined by the investigator
- Non-native English speakers are permitted to enroll if they have achieved native fluency. 7. Vitals as collected by the clinic using Duke maintained equipment must be within the ranges specified by the remote patient monitoring devices.
- Weight ≤ 180 kg
- Systolic blood pressure ≤ 300 mmHg
- Pulse rate of 40-200 bpm
- SpO2 of 70-100%
- Temperature 34.0-42.2°C 8. Arm circumference of 22-42 cm
1. 1\. Vision, speech, auditory, physical, cognitive or other impairment that has the potential to interfere with the use of the remote patient monitoring device or agent, in the opinion of the investigator or study coordinator. 2. Has an implanted pacemaker, arterio-venus (A-V) shunt, a history of mastectomy or lymph node clearance, history of severe blood flow problems or blood disorders, or a history of severe circulatory deficit in the arm. 3. Is pregnant
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Duke University Medical CenterDurham, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 29, 2026. Always confirm current availability with the study team.